Article info

Download PDFPDF
Effects of a motilin receptor agonist (ABT-229) on upper gastrointestinal symptoms in type 1 diabetes mellitus: a randomised, double blind, placebo controlled trial

Authors

  • N J Talley aDepartment of Medicine, University of Sydney, Nepean Hospital, Penrith NSW, Australia, bAbbott Laboratories, Abbott Park Illinois, USA, cGastroenterology Consultants Ltd, Milwaukee, Wisconsin, USA, dMississippi Center for Clinical Research, Jackson, Mississippi, USA, eAssociated Gastroenterology Group, Anaheim, California, USA, fUniversity of Kansas Medical Center, Kansas City, Kansas, USA PubMed articlesGoogle scholar articles
  • M Verlinden aDepartment of Medicine, University of Sydney, Nepean Hospital, Penrith NSW, Australia, bAbbott Laboratories, Abbott Park Illinois, USA, cGastroenterology Consultants Ltd, Milwaukee, Wisconsin, USA, dMississippi Center for Clinical Research, Jackson, Mississippi, USA, eAssociated Gastroenterology Group, Anaheim, California, USA, fUniversity of Kansas Medical Center, Kansas City, Kansas, USA PubMed articlesGoogle scholar articles
  • D J Geenen aDepartment of Medicine, University of Sydney, Nepean Hospital, Penrith NSW, Australia, bAbbott Laboratories, Abbott Park Illinois, USA, cGastroenterology Consultants Ltd, Milwaukee, Wisconsin, USA, dMississippi Center for Clinical Research, Jackson, Mississippi, USA, eAssociated Gastroenterology Group, Anaheim, California, USA, fUniversity of Kansas Medical Center, Kansas City, Kansas, USA PubMed articlesGoogle scholar articles
  • R B Hogan aDepartment of Medicine, University of Sydney, Nepean Hospital, Penrith NSW, Australia, bAbbott Laboratories, Abbott Park Illinois, USA, cGastroenterology Consultants Ltd, Milwaukee, Wisconsin, USA, dMississippi Center for Clinical Research, Jackson, Mississippi, USA, eAssociated Gastroenterology Group, Anaheim, California, USA, fUniversity of Kansas Medical Center, Kansas City, Kansas, USA PubMed articlesGoogle scholar articles
  • D Riff aDepartment of Medicine, University of Sydney, Nepean Hospital, Penrith NSW, Australia, bAbbott Laboratories, Abbott Park Illinois, USA, cGastroenterology Consultants Ltd, Milwaukee, Wisconsin, USA, dMississippi Center for Clinical Research, Jackson, Mississippi, USA, eAssociated Gastroenterology Group, Anaheim, California, USA, fUniversity of Kansas Medical Center, Kansas City, Kansas, USA PubMed articlesGoogle scholar articles
  • R W McCallum aDepartment of Medicine, University of Sydney, Nepean Hospital, Penrith NSW, Australia, bAbbott Laboratories, Abbott Park Illinois, USA, cGastroenterology Consultants Ltd, Milwaukee, Wisconsin, USA, dMississippi Center for Clinical Research, Jackson, Mississippi, USA, eAssociated Gastroenterology Group, Anaheim, California, USA, fUniversity of Kansas Medical Center, Kansas City, Kansas, USA PubMed articlesGoogle scholar articles
  • R J Mack aDepartment of Medicine, University of Sydney, Nepean Hospital, Penrith NSW, Australia, bAbbott Laboratories, Abbott Park Illinois, USA, cGastroenterology Consultants Ltd, Milwaukee, Wisconsin, USA, dMississippi Center for Clinical Research, Jackson, Mississippi, USA, eAssociated Gastroenterology Group, Anaheim, California, USA, fUniversity of Kansas Medical Center, Kansas City, Kansas, USA PubMed articlesGoogle scholar articles
  1. Professor N J Talley, Department of Medicine, University of Sydney, Nepean Hospital, PO Box 63, Penrith NSW 2751, Australia.
View Full Text

Citation

Talley NJ, Verlinden M, Geenen DJ, et al
Effects of a motilin receptor agonist (ABT-229) on upper gastrointestinal symptoms in type 1 diabetes mellitus: a randomised, double blind, placebo controlled trial

Publication history

  • Accepted December 5, 2000
  • First published September 1, 2001.
Online issue publication 
January 10, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.